Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate long-term safety of alemtuzumab.
Secondary Objectives:
- To evaluate long term efficacy of alemtuzumab.
- To evaluate the safety profile of participants who received other Disease Modifying
Treatment (DMT) following alemtuzumab treatment.
- To evaluate participant-reported Quality of Life (QoL) outcomes and health resource
utilization of participant who received alemtuzumab.
- To evaluate as needed re-treatment with alemtuzumab and other DMTs.